Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 733 shares at $314.22 ($231K) on 2023-04-04, disclosed to the SEC on 2023-04-06.
Scheduled sale ($231k) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $314.22 | 211 | $66K | 28.7% |
| 2 | $314.22 | 211 | $66K | 28.7% |
| 3 | $315.66 | 94 | $30K | 12.8% |
| 4 | $316.76 | 90 | $29K | 12.3% |
| 5 | $317.65 | 96 | $30K | 13.2% |
| 6 | $318.68 | 31 |
| $10K |
| 4.3% |
| Total | $315.35 avg | 733 | $231K | 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |
| VRTX | SELL | 2023-02-16 | $1.3M | — | Filing → |